Literature DB >> 9606024

Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development.

B Grimaldi1, A Bonnin, M P Fillion, M Ruat, E Traiffort, G Fillion.   

Abstract

We have determined the pharmacological characteristics of the rat 5-ht6 receptor stably expressed in CHO cells. Moreover, using RT-PCR experiments the in vivo expression of the gene encoding this receptor was studied in rat at various embryonic days (ED) starting from ED10 to birth (PN0) and at post-natal days (PN) up to PN36. The pharmacological analysis of the [3H]5-HT binding in stably transfected CHO cells expressing rat 5-ht6 receptors revealed the presence of a single class of high affinity saturable binding sites for 5-HT corresponding to an affinity constant: Kd=27.2+/-3.4 nM. This receptor also exhibited a high affinity for a number of typical and atypical antipsychotics, tricyclic antidepressant drugs and ergot alkaloïds. In stably transfected CHO cells, serotonin elicited a potent stimulation of adenylyl cyclase activity which was blocked by antipsychotic and antidepressant drugs. These results confirm the hypothesis that 5-ht6 receptors may correspond to an important target for atypical antipsychotics and reveal an original pharmacological profile for this receptor. The study of the ontogeny of the 5-ht6 mRNA in rat developing brain showed that 5-ht6 mRNA were first detectable with a high level on ED12, slighly decreased up to ED17 and then remained stable at high level until the adult age. The ontogenetic pattern of 5-ht6 mRNA expression appeared to correlate with the occurence of the first cell bodies of serotonergic neurons; the early expression of 5-ht6 mRNA and the fact that this receptor is positively coupled to the production of cAMP may suggest a role for 5-ht6 receptor in the early growth process involving the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9606024     DOI: 10.1007/pl00005184

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  5-HT6 receptor blockade regulates primary cilia morphology in striatal neurons.

Authors:  Matthew Brodsky; Adam J Lesiak; Alex Croicu; Nathalie Cohenca; Jane M Sullivan; John F Neumaier
Journal:  Brain Res       Date:  2017-01-10       Impact factor: 3.252

2.  Neuronal differentiation: 5-HT6R can do it alone.

Authors:  Jinsoo Seo; Li-Huei Tsai
Journal:  Nat Chem Biol       Date:  2014-07       Impact factor: 15.040

3.  Restoration of Physiological Expression of 5-HT6 Receptor into the Primary Cilia of Null Mutant Neurons Lengthens Both Primary Cilia and Dendrites.

Authors:  Atom J Lesiak; Matthew Brodsky; Nathalie Cohenca; Alexandra G Croicu; John F Neumaier
Journal:  Mol Pharmacol       Date:  2018-04-20       Impact factor: 4.436

4.  Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.

Authors:  I Verde; G Vandecasteele; F Lezoualc'h; R Fischmeister
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

5.  In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer's Disease.

Authors:  Tijana Bojić; Milan Sencanski; Vladimir Perovic; Jelena Milicevic; Sanja Glisic
Journal:  Molecules       Date:  2022-04-19       Impact factor: 4.927

6.  DISC1 regulates primary cilia that display specific dopamine receptors.

Authors:  Aaron Marley; Mark von Zastrow
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

7.  Serotonin homeostasis and serotonin receptors as actors of cortical construction: special attention to the 5-HT3A and 5-HT6 receptor subtypes.

Authors:  Tania Vitalis; Mark S Ansorge; Alexandre G Dayer
Journal:  Front Cell Neurosci       Date:  2013-06-19       Impact factor: 5.505

8.  The serotonin-6 receptor as a novel therapeutic target.

Authors:  Hyung-Mun Yun; Hyewhon Rhim
Journal:  Exp Neurobiol       Date:  2011-12-29       Impact factor: 3.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.